Use of gdf-15 as a novel biomarker
OwnerReem MAHRATinventor
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to use of GDF-15 as a novel biomarker for diagnosing, monitoring early-stage cancer, insulin resistance, and autoimmune diseases. Further, the present disclosure also relates to a multipurpose kit and personalized treatment across multiple health domains. Additionally, the present disclosure deals with an AI-driven personalized treatment and point of care (POC) platform using GDF-15 biomarker. There is a disclosure about dual biomarker system comprising GDF 15 and additional biomarker.
Claims18
A method for assessing biological aging in a subject, comprising:
- obtaining a biological sample from the subject, where the sample is selected from the group consisting of blood, urine, saliva, or other bodily fluids;
- measuring Growth Differentiation Factor 15(GDF15 ) levels in the sample;
- comparing the measured GDF15 levels to a predetermined baseline indicative of biological age;
- and
- determining the biological age of the subject based on the correlation between GDF15 levels and established biological age markers.
A method for predicting age-related health outcomes in a subject, comprising:
- measuring GDF15 levels in a biological sample, wherein the biological sample is selected from the group consisting of blood or urine, from the subject;
- correlating the measured GDF15 levels with the likelihood of developing age-related conditions, wherein the age-related conditions are selected from the group consisting of cardiovascular disease, sarcopenia, osteoporosis, and cognitive decline;
- and
- providing targeted health recommendations based on the assessed risk of age-related conditions.
A method for predicting early-onset menopausal symptoms in a subject, comprising:
- measuring GDF15 levels in a biological sample from the subject;
- comparing the measured GDF15 levels to predetermined thresholds associated with risk for early-onset menopause;
- and
- determining the subject's risk of developing early-onset menopausal symptoms based on elevated GDF15 levels.
Dependencies are inferred from the claim text.